Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 7/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.44 |
| ▸ | DDR1 | Q08345 | 5/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.37 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.37 |
| ▸ | AGBL2 | Q5U5Z8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8534421 | 0.90 | SLC6A2 (0.54) | SLC6A4SLC6A2DDR1SLC6A3 | |
| SCHEMBL4437981 | 0.86 | SLC6A4 (0.53) | SLC6A4SLC6A2SLC6A3AGBL2 | |
| SCHEMBL4446608 | 0.84 | SLC6A4 (0.53) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL11710235 | 0.81 | SLC6A4 (0.49) | SLC6A4SLC6A2DDR1SLC6A3 | |
| SCHEMBL4436403 | 0.80 | SLC6A4 (0.48) | SLC6A4SLC6A2SLC6A3AGBL2 | |
| SCHEMBL3681970 | 0.79 | IDO1 (0.52) | SLC6A4SLC6A2DDR1SLC6A3IDO1 | |
| SCHEMBL4440532 | 0.78 | SLC6A4 (0.47) | SLC6A4SLC6A2SLC6A3AGBL2 | |
| SCHEMBL4437710 | 0.78 | APOBEC3G (0.52) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL4439390 | 0.78 | SLC6A4 (0.47) | SLC6A4SLC6A2SLC6A3AGBL2 | |
| Bromide SCHEMBL4439279 | 0.78 | IDO1 (0.51) | SLC6A4SLC6A2DDR1SLC6A3IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101622227-A | Biaryl and biheteroaryl compounds useful in treating iron disorders | XENON PHARMACEUTICALS INC | 2010-01-06 | — | — | CN | disclosed |
| EP-2061754-A1 | BIARYL AND BIHETEROARYL COMPOUNDS USEFUL IN TREATING IRON DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2009-05-27 | — | — | EP | disclosed |
| WO-2008115999-A1 | BIARYL AND BIHETEROARYL COMPOUNDS USEFUL IN TREATING IRON DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2008-09-25 | — | — | WO | disclosed |
| US-20080234384-A1 | BIARYL AND BIHETEROARYL COMPOUNDS USEFUL IN TREATING IRON DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234384-A1 | BIARYL AND BIHETEROARYL COMPOUNDS USEFUL IN TREATING IRON DISORDERS | FECH, SLC10A1, SLC40A1 | SLC6A4 724/4885SLC6A2 247/4885DDR1 4879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.